**THE CLAIMS:**

This listing will replace all prior versions and listings of claims in the application.

**LISTING OF CLAIMS:**

1-17. (Cancelled)

18. (Currently Amended) The method of claim 32 ~~16 or 17~~, wherein said fluorescently-labeled steroid hormone receptor ligand includes a fluorescent label selected from the group consisting of fluorescein, fluoresceinamine, DTAF, Texas Red, BODIPY dyes, Alexa dyes, tetramethylrhodamine (TMR), and conjugatable derivatives thereof.

19. (Currently Amended) The method of claim 32 ~~17~~, wherein said ligand binding domain (LBD) of a steroid hormone receptor is fused to an N-terminal domain selected from the group consisting of glutathione-S-transferase (GST), maltose binding protein (MBP), and thioredoxin (TRX).

20. (Currently Amended) The method of claim 32 ~~16 or 17~~, wherein said fluorescently-labeled steroid hormone receptor ligand includes a steroid selected from the group consisting of 5α-androstan and derivatives thereof, 4-androsten and derivatives thereof, 4-pregnen and derivatives thereof, and dexamethasone and derivatives thereof.

21. (Cancelled)

22. (Currently Amended) The method of claim 32 ~~16 or 17~~, wherein said fluorescently-labeled steroid hormone receptor ligand binds to said LBD ~~steroid hormone~~ with a $K_d$ of less than 20nM.

23. (Cancelled)

24. (Currently Amended) The method of claim 32 ~~16 or 17~~, wherein said fluorescently-labeled steroid hormone receptor ligand is capable of competing with a known ligand of said steroid hormone receptor for binding to said steroid hormone receptor.

25. (Currently Amended) The method of claim 18, said fluorescent label is conjugated to said steroid hormone receptor ligand via a linker.

26. (Previously Presented) The method of claim 20, wherein said steroid is 5α-androstan derivatized at one or more of the 1, 3, 6, 7, 11, 15, 17, 18, or 19 positions with a linker conjugated to a fluorescent label.

27. (Previously Presented) The method of claim 20, wherein said steroid is 4-adrosten derivatized at one or more of the 1, 3, 6, 7, 11, 15, 17, 18, or 19 positions with a linker conjugated to a fluorescent label.

28. (Previously Presented) The method of claim 20, wherein said steroid is 4-pregnen derivatized at one or more of the 3, 6, 7, 11, 17, 19, 20 or 21 positions with a linker conjugated to a fluorescent label.

29. (Previously Presented) The method of claim 20, wherein said steroid is dexamethasone derivatized at position 21 with a linker conjugated to a fluorescent label.

30. (Previously Presented) The method of claim 22, wherein said $K_d$ is 0.8±0.1 nM and wherein said steroid hormone receptor is GR.

31. (Previously Presented) The method of claim 22, wherein said $K_d$ is 2.5 nM and wherein said steroid hormone receptor is PR.

32. (New) A method for monitoring a binding interaction of a steroid hormone receptor (SHR) with a test ligand comprising:

(a) a first mixture comprising a fluorescently-labeled steroid hormone receptor ligand, a test compound and a ligand binding domain (LBD) of a steroid hormone receptor selected from the group consisting of an androgen receptor (AR), a glucocorticoid receptor (GR), and a progesterone receptor (PR), and

(b) measuring the fluorescence polarization of the first mixture.

33. (New) The method of claim 32, further comprising:

(c) a second mixture comprising a fluorescently-labeled steroid hormone receptor ligand and said ligand binding domain (LBD) of a steroid hormone receptor, and

(d) measuring the fluorescence polarization of the second mixture.

34. (New) The method of claim 33, further comprising:

(e) comparing the fluorescence polarization of said second mixture and the fluorescence polarization of said first mixture to determine if the test compound affects binding of said fluorescently-labeled steroid hormone receptor ligand to the LBD of a steroid hormone receptor.

35. (New) The method of claim 33, wherein the LBD is a full length steroid hormone receptor.